98 related articles for article (PubMed ID: 6428793)
1. Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon.
Luderer JR; Nicholas GG; Neumyer MM; Riley DL; Vary JE; Garcia G; Schneck DW
Clin Pharmacol Ther; 1984 Jul; 36(1):105-15. PubMed ID: 6428793
[TBL] [Abstract][Full Text] [Related]
2. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon.
Tindall H; Tooke JE; Menys VC; Martin MF; Davies JA
Eur J Clin Invest; 1985 Feb; 15(1):20-3. PubMed ID: 3921380
[TBL] [Abstract][Full Text] [Related]
3. Effect of thromboxane synthetase inhibition in Raynaud's phenomenon.
Coffman JD; Rasmussen HM
Clin Pharmacol Ther; 1984 Sep; 36(3):369-73. PubMed ID: 6467796
[TBL] [Abstract][Full Text] [Related]
4. Plasma 6 keto PGE1 alpha concentration in Raynaud's phenomenon.
Kinney EL; Demers LM
Prostaglandins Med; 1981 Nov; 7(5):389-93. PubMed ID: 6895673
[TBL] [Abstract][Full Text] [Related]
5. A thromboxane synthetase inhibitor in Raynaud's phenomenon.
Jones EW; Hawkey CJ
Prostaglandins Leukot Med; 1983 Sep; 12(1):67-71. PubMed ID: 6356154
[TBL] [Abstract][Full Text] [Related]
6. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation.
Malamet R; Wise RA; Ettinger WH; Wigley FM
Am J Med; 1985 Apr; 78(4):602-8. PubMed ID: 3157318
[TBL] [Abstract][Full Text] [Related]
7. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon.
Ettinger WH; Wise RA; Schaffhauser D; Wigley FM
Am J Med; 1984 Sep; 77(3):451-6. PubMed ID: 6540986
[TBL] [Abstract][Full Text] [Related]
8. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
9. [Effect of dazoxiben on the metabolism of arachidonic acid in isolated porcine basilar arteries].
Rui YC; Sun DX; Lin AY
Zhongguo Yao Li Xue Bao; 1990 May; 11(3):261-4. PubMed ID: 2128432
[TBL] [Abstract][Full Text] [Related]
10. Comparison of radioimmunoassay and high-resolution gas chromatography mass spectrometry for the quantitative determination of serum thromboxane B2 and 6-keto-PGF1 alpha after pharmacological blockade of thromboxane synthetase.
Chiabrando C; Castagnoli MN; Noseda A; Fanelli R; Rajtar G; Cerletti C; de Gaetano G
Prostaglandins Leukot Med; 1984 Oct; 16(1):79-88. PubMed ID: 6440153
[TBL] [Abstract][Full Text] [Related]
11. Epoprostenol in patients with Raynaud's disease.
Fitscha P; Kaliman J; Weidinger F; Sinzinger H; O'Grady J
Prostaglandins Leukot Essent Fatty Acids; 1988 Jul; 33(1):23-7. PubMed ID: 3141936
[TBL] [Abstract][Full Text] [Related]
12. Arachidonic acid metabolism following aneurysm rupture. Evaluation of cerebrospinal fluid and serum concentration of 6-keto-prostaglandin F1 alpha and thromboxane B2 in patients with subarachnoid hemorrhage.
Seifert V; Stolke D; Kaever V; Dietz H
Surg Neurol; 1987 Mar; 27(3):243-52. PubMed ID: 3810456
[TBL] [Abstract][Full Text] [Related]
13. Plasma eicosanoids, platelet function and cold sensitivity.
Wilkinson D; Vowden P; Gilks L; Latif AB; Rajah SM; Kester RC
Br J Surg; 1989 Apr; 76(4):401-5. PubMed ID: 2720355
[TBL] [Abstract][Full Text] [Related]
14. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.
Bush LR; Campbell WB; Buja LM; Tilton GD; Willerson JT
Circulation; 1984 Jun; 69(6):1161-70. PubMed ID: 6546902
[TBL] [Abstract][Full Text] [Related]
15. [Effect of dazoxiben on cerebrovascular resistance in rabbits].
Rui YC; Sun DX; Long K
Zhongguo Yao Li Xue Bao; 1989 Jul; 10(4):342-5. PubMed ID: 2624120
[TBL] [Abstract][Full Text] [Related]
16. Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis.
Dodd NJ; Gordge MP; Weston MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):67S-70S. PubMed ID: 6337605
[TBL] [Abstract][Full Text] [Related]
17. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.
Belch JJ; Cormie J; Newman P; McLaren M; Barbenel J; Capell H; Leiberman P; Forbes CD; Prentice CR
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):113S-116S. PubMed ID: 6337601
[TBL] [Abstract][Full Text] [Related]
18. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
19. Modulation of arachidonic acid metabolism in endotoxic horses: comparison of flunixin meglumine, phenylbutazone, and a selective thromboxane synthetase inhibitor.
Moore JN; Hardee MM; Hardee GE
Am J Vet Res; 1986 Jan; 47(1):110-3. PubMed ID: 3080926
[TBL] [Abstract][Full Text] [Related]
20. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat.
Maguire ED; Wallis RB
Thromb Res; 1983 Oct; 32(1):15-27. PubMed ID: 6689221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
